Impact of combinatorial immunotherapies in breast cancer: a systematic review and meta-analysis
BackgroundBreast cancer has the highest mortality rate among all cancers affecting females worldwide. Several new effective therapeutic strategies are being developed to minimize the number of breast cancer-related deaths and improve the quality of life of breast cancer patients. However, resistance...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-10-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1469441/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850284029694181376 |
|---|---|
| author | Sandeep Sisodiya Sandeep Sisodiya Vishakha Kasherwal Vishakha Kasherwal Jyoti Rani Jyoti Rani Neetu Mishra Sandeep Kumar Asiya Khan Mehreen Aftab Shagufta Shagufta Payal Singh Ekta Gupta Pranay Tanwar Showket Hussain |
| author_facet | Sandeep Sisodiya Sandeep Sisodiya Vishakha Kasherwal Vishakha Kasherwal Jyoti Rani Jyoti Rani Neetu Mishra Sandeep Kumar Asiya Khan Mehreen Aftab Shagufta Shagufta Payal Singh Ekta Gupta Pranay Tanwar Showket Hussain |
| author_sort | Sandeep Sisodiya |
| collection | DOAJ |
| description | BackgroundBreast cancer has the highest mortality rate among all cancers affecting females worldwide. Several new effective therapeutic strategies are being developed to minimize the number of breast cancer-related deaths and improve the quality of life of breast cancer patients. However, resistance to conventional therapies in breast cancer patients remains a challenge which could be due to several reasons, including changes in the tumor microenvironment. Attention is being diverted towards minimizing the resistance, toxicity, and improving the affordability of therapeutics for better breast cancer management. This includes personalized medicine, target-specific drug delivery systems, combinational therapies and artificial intelligence based screening and disease prediction. Nowadays, researchers and clinicians are also exploring the use of combinatorial immunotherapies in breast cancer patients, which have shown encouraging results in terms of improved survival outcomes. This study attempts to analyze the role of combinational immunotherapies in breast cancer patients, and offer insights into their effectiveness in breast cancer management.MethodologyWe conducted a systematic review and meta-analysis for which we selected the randomized clinical trials (RCTs) focused on completed Phase I/II/III/IV clinical trials investigating combination immunotherapies for breast cancer. The analysis aimed to assess the efficacy of combination therapies in comparison to mono-therapies, focusing on overall survival (OS), and progression-free survival (PFS).ResultsWe observed that, combination immunotherapies significantly (P<0.05) improved OS as compared to single-drug therapies in the Phase I with overall Risk ratio (RR) of 16.17 (CI 2.23,117.50), Phase II with an overall RR of 19.19 (CI 11.76,31.30) and for phase III overall RR 22.27 (CI 13.60,36.37). In the case of PFS, it was significant with RR: 12.35 (CI 2.14, 71.26) in Phase I RR 6.10 (CI 4.31, 8.64) in phase II, RR 8.95 (CI 6.09, 13.16) in phase III and RR 14.82 (CI 6.49, 33.82) in Phase IV of clinical trials.ConclusionThe observed improvements in overall survival and progression-free survival suggest that combination immunotherapies could serve as a better approach to breast cancer management. |
| format | Article |
| id | doaj-art-9f03349f52804f10a2cd847d2a5da40c |
| institution | OA Journals |
| issn | 1664-3224 |
| language | English |
| publishDate | 2024-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-9f03349f52804f10a2cd847d2a5da40c2025-08-20T01:47:40ZengFrontiers Media S.A.Frontiers in Immunology1664-32242024-10-011510.3389/fimmu.2024.14694411469441Impact of combinatorial immunotherapies in breast cancer: a systematic review and meta-analysisSandeep Sisodiya0Sandeep Sisodiya1Vishakha Kasherwal2Vishakha Kasherwal3Jyoti Rani4Jyoti Rani5Neetu Mishra6Sandeep Kumar7Asiya Khan8Mehreen Aftab9 Shagufta10 Shagufta11Payal Singh12Ekta Gupta13Pranay Tanwar14Showket Hussain15Cellular and Molecular Diagnostics (Molecular Biology Group), ICMR-National Institute of Cancer Prevention and Research, Noida, IndiaSymbiosis School of Biological Sciences, Symbiosis International (Deemed University) (SIU), Pune, IndiaCellular and Molecular Diagnostics (Molecular Biology Group), ICMR-National Institute of Cancer Prevention and Research, Noida, IndiaSymbiosis School of Biological Sciences, Symbiosis International (Deemed University) (SIU), Pune, IndiaCellular and Molecular Diagnostics (Molecular Biology Group), ICMR-National Institute of Cancer Prevention and Research, Noida, IndiaDepartment of Zoology, Meerut College, C.C.S. University, Meerut, IndiaSymbiosis School of Biological Sciences, Symbiosis International (Deemed University) (SIU), Pune, IndiaCellular and Molecular Diagnostics (Molecular Biology Group), ICMR-National Institute of Cancer Prevention and Research, Noida, IndiaLaboratory Oncology Unit, Dr. BRA-IRCH, All India Institute of Medical Sciences, New Delhi, IndiaCellular and Molecular Diagnostics (Molecular Biology Group), ICMR-National Institute of Cancer Prevention and Research, Noida, IndiaCellular and Molecular Diagnostics (Molecular Biology Group), ICMR-National Institute of Cancer Prevention and Research, Noida, IndiaDepatment of Life Sciences, School of Basic Sciences and Research (SBSR), Sharda University, Greater Noida, IndiaCellular and Molecular Diagnostics (Molecular Biology Group), ICMR-National Institute of Cancer Prevention and Research, Noida, IndiaDivision of Clinical Oncology, ICMR-National Institute of Cancer Prevention and Research, Noida, IndiaLaboratory Oncology Unit, Dr. BRA-IRCH, All India Institute of Medical Sciences, New Delhi, IndiaCellular and Molecular Diagnostics (Molecular Biology Group), ICMR-National Institute of Cancer Prevention and Research, Noida, IndiaBackgroundBreast cancer has the highest mortality rate among all cancers affecting females worldwide. Several new effective therapeutic strategies are being developed to minimize the number of breast cancer-related deaths and improve the quality of life of breast cancer patients. However, resistance to conventional therapies in breast cancer patients remains a challenge which could be due to several reasons, including changes in the tumor microenvironment. Attention is being diverted towards minimizing the resistance, toxicity, and improving the affordability of therapeutics for better breast cancer management. This includes personalized medicine, target-specific drug delivery systems, combinational therapies and artificial intelligence based screening and disease prediction. Nowadays, researchers and clinicians are also exploring the use of combinatorial immunotherapies in breast cancer patients, which have shown encouraging results in terms of improved survival outcomes. This study attempts to analyze the role of combinational immunotherapies in breast cancer patients, and offer insights into their effectiveness in breast cancer management.MethodologyWe conducted a systematic review and meta-analysis for which we selected the randomized clinical trials (RCTs) focused on completed Phase I/II/III/IV clinical trials investigating combination immunotherapies for breast cancer. The analysis aimed to assess the efficacy of combination therapies in comparison to mono-therapies, focusing on overall survival (OS), and progression-free survival (PFS).ResultsWe observed that, combination immunotherapies significantly (P<0.05) improved OS as compared to single-drug therapies in the Phase I with overall Risk ratio (RR) of 16.17 (CI 2.23,117.50), Phase II with an overall RR of 19.19 (CI 11.76,31.30) and for phase III overall RR 22.27 (CI 13.60,36.37). In the case of PFS, it was significant with RR: 12.35 (CI 2.14, 71.26) in Phase I RR 6.10 (CI 4.31, 8.64) in phase II, RR 8.95 (CI 6.09, 13.16) in phase III and RR 14.82 (CI 6.49, 33.82) in Phase IV of clinical trials.ConclusionThe observed improvements in overall survival and progression-free survival suggest that combination immunotherapies could serve as a better approach to breast cancer management.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1469441/fullCombinational therapyimmunotherapybreast cancersystematic reviewmeta-analysis |
| spellingShingle | Sandeep Sisodiya Sandeep Sisodiya Vishakha Kasherwal Vishakha Kasherwal Jyoti Rani Jyoti Rani Neetu Mishra Sandeep Kumar Asiya Khan Mehreen Aftab Shagufta Shagufta Payal Singh Ekta Gupta Pranay Tanwar Showket Hussain Impact of combinatorial immunotherapies in breast cancer: a systematic review and meta-analysis Frontiers in Immunology Combinational therapy immunotherapy breast cancer systematic review meta-analysis |
| title | Impact of combinatorial immunotherapies in breast cancer: a systematic review and meta-analysis |
| title_full | Impact of combinatorial immunotherapies in breast cancer: a systematic review and meta-analysis |
| title_fullStr | Impact of combinatorial immunotherapies in breast cancer: a systematic review and meta-analysis |
| title_full_unstemmed | Impact of combinatorial immunotherapies in breast cancer: a systematic review and meta-analysis |
| title_short | Impact of combinatorial immunotherapies in breast cancer: a systematic review and meta-analysis |
| title_sort | impact of combinatorial immunotherapies in breast cancer a systematic review and meta analysis |
| topic | Combinational therapy immunotherapy breast cancer systematic review meta-analysis |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1469441/full |
| work_keys_str_mv | AT sandeepsisodiya impactofcombinatorialimmunotherapiesinbreastcancerasystematicreviewandmetaanalysis AT sandeepsisodiya impactofcombinatorialimmunotherapiesinbreastcancerasystematicreviewandmetaanalysis AT vishakhakasherwal impactofcombinatorialimmunotherapiesinbreastcancerasystematicreviewandmetaanalysis AT vishakhakasherwal impactofcombinatorialimmunotherapiesinbreastcancerasystematicreviewandmetaanalysis AT jyotirani impactofcombinatorialimmunotherapiesinbreastcancerasystematicreviewandmetaanalysis AT jyotirani impactofcombinatorialimmunotherapiesinbreastcancerasystematicreviewandmetaanalysis AT neetumishra impactofcombinatorialimmunotherapiesinbreastcancerasystematicreviewandmetaanalysis AT sandeepkumar impactofcombinatorialimmunotherapiesinbreastcancerasystematicreviewandmetaanalysis AT asiyakhan impactofcombinatorialimmunotherapiesinbreastcancerasystematicreviewandmetaanalysis AT mehreenaftab impactofcombinatorialimmunotherapiesinbreastcancerasystematicreviewandmetaanalysis AT shagufta impactofcombinatorialimmunotherapiesinbreastcancerasystematicreviewandmetaanalysis AT shagufta impactofcombinatorialimmunotherapiesinbreastcancerasystematicreviewandmetaanalysis AT payalsingh impactofcombinatorialimmunotherapiesinbreastcancerasystematicreviewandmetaanalysis AT ektagupta impactofcombinatorialimmunotherapiesinbreastcancerasystematicreviewandmetaanalysis AT pranaytanwar impactofcombinatorialimmunotherapiesinbreastcancerasystematicreviewandmetaanalysis AT showkethussain impactofcombinatorialimmunotherapiesinbreastcancerasystematicreviewandmetaanalysis |